Anti-fibrotic nintedanib—a new opportunity for systemic sclerosis patients?
- 621 Downloads
Systemic sclerosis is a connective tissue disease characterized by progressive skin thickening and a wide spectrum of internal organ involvement. Pathogenesis includes vasculopathy, inflammation, and fibrosis. Although immunosuppressants such as cyclophosphamide and mycophenolate mofetil have shown some benefit in interstitial lung disease management, it is still a major cause of morbi-mortality in these patients. Therefore, there is a current need for new therapies. Here, we report a 65-year-old female patient with limited cutaneous systemic sclerosis, anti-topoisomerase-positive and extensive lung disease. The patient developed progressive lung fibrosis under several immunosuppressants and was started on nintedanib, with clinical and functional stabilization. Nintedanib is a tyrosine-kinase inhibitor that blocks several profibrotic pathways, inhibiting proliferation and migration of fibroblasts and decreasing the synthesis of extracellular matrix proteins. It is approved for idiopathic lung fibrosis and has demonstrated good results in inhibiting migration and proliferation of systemic sclerosis dermal fibroblasts, constituting a promising agent for systemic sclerosis-associated lung fibrosis.
KeywordsAnti-fibrotic therapy Interstitial lung disease Nintedanib Systemic sclerosis
Compliance with ethical standards
- 4.Bonella F, Stowasser S, Wollin L (2015) Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib [Internet]. Drug Design, Development and Therapy. [cited 2017 Aug 26]. Available from: https://www.dovepress.com/idiopathic-pulmonary-fibrosis-current-treatment-options-and-critical-a-peer-reviewed-fulltext-article-DDDT
- 12.Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NSL et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962–3970CrossRefPubMedGoogle Scholar
- 13.Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, et al (2015) Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 44(4):428–36. 9Google Scholar
- 27.Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, et al (2016) An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol. jrheum.151322Google Scholar
- 32.Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, et al (2017) Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCISTM). Clin Exp RheumatolGoogle Scholar